Astrocyte´s RAGE: More than just a question of mood

Rodrigo E. González-Reyes, María Graciela Rubiano

Resultado de la investigación: Contribución a RevistaArtículo

  • 3 Citas

Resumen

Adequate function of the nervous system depends on the balance of glia-neuron complex interactions. Astrocytes, in particular, are key elements in this process due to the significant participation of these cells in essential properties of the nervous system such as neuroinflammation, regulation of neurotransmitters, release of gliotransmitters and control of synaptic plasticity, among others. Astrocytes express the receptor for advanced glycation end products (RAGE) which is very important in the recognition of endogenous molecules released in the context of infection, physiological stress or chronic inflammation. RAGE can bind several advanced glycation end products, S100 proteins, HMGB1, amyloid-β and other additional DAMP molecules. The nuclear factor-kappa B (NF-κB) transcription pathway is the main intracellular signaling pathway activated by the RAGE receptor, inducing an increase in the expression and release of proinflammatory cytokines. Due to its numerous interactions, RAGE is suspected to be involved in various physiological and pathological processes. It is plausible that a prolonged exposure to RAGE ligands or abnormally increased concentrations of some ligands may induce lengthy periods of intracellular proinflammatory activation, which may induce the appearance of reactive astrocytes involved in the development and/or progression of neurodegenerative disorders. Blocking or reducing the duration of activation of RAGE/NF-κB signaling in astrocytes may become an important therapeutic alternative for the treatment of neurodegenerative disorders in the future.

IdiomaEnglish (US)
Páginas39
Número de páginas48
PublicaciónCentral Nervous System Agents in Medicinal Chemistry
Volumen18
Número de edición1
DOI
EstadoPublished - ene 26 2018
Publicado de forma externa

Huella dactilar

Astrocytes
Neurodegenerative Diseases
Nervous System
Physiological Phenomena
HMGB1 Protein
Ligands
Physiological Stress
Advanced Glycosylation End Products
Neuronal Plasticity
S100 Proteins
NF-kappa B
Pathologic Processes
Amyloid
Neuroglia
Neurotransmitter Agents
Advanced Glycosylation End Product-Specific Receptor
Cytokines
Inflammation
Neurons
Infection

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology
  • Molecular Medicine

Citar esto

@article{a86ef4bdb6034ac489b5f337edbc38a0,
title = "Astrocyte´s RAGE: More than just a question of mood",
abstract = "Adequate function of the nervous system depends on the balance of glia-neuron complex interactions. Astrocytes, in particular, are key elements in this process due to the significant participation of these cells in essential properties of the nervous system such as neuroinflammation, regulation of neurotransmitters, release of gliotransmitters and control of synaptic plasticity, among others. Astrocytes express the receptor for advanced glycation end products (RAGE) which is very important in the recognition of endogenous molecules released in the context of infection, physiological stress or chronic inflammation. RAGE can bind several advanced glycation end products, S100 proteins, HMGB1, amyloid-β and other additional DAMP molecules. The nuclear factor-kappa B (NF-κB) transcription pathway is the main intracellular signaling pathway activated by the RAGE receptor, inducing an increase in the expression and release of proinflammatory cytokines. Due to its numerous interactions, RAGE is suspected to be involved in various physiological and pathological processes. It is plausible that a prolonged exposure to RAGE ligands or abnormally increased concentrations of some ligands may induce lengthy periods of intracellular proinflammatory activation, which may induce the appearance of reactive astrocytes involved in the development and/or progression of neurodegenerative disorders. Blocking or reducing the duration of activation of RAGE/NF-κB signaling in astrocytes may become an important therapeutic alternative for the treatment of neurodegenerative disorders in the future.",
author = "Gonz{\'a}lez-Reyes, {Rodrigo E.} and Rubiano, {Mar{\'i}a Graciela}",
year = "2018",
month = "1",
day = "26",
doi = "10.2174/1871524916999160505105121",
language = "English (US)",
volume = "18",
pages = "39",
journal = "Central Nervous System Agents in Medicinal Chemistry",
issn = "1871-5249",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

Astrocyte´s RAGE : More than just a question of mood. / González-Reyes, Rodrigo E.; Rubiano, María Graciela.

En: Central Nervous System Agents in Medicinal Chemistry, Vol. 18, N.º 1, 26.01.2018, p. 39.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - Astrocyte´s RAGE

T2 - Central Nervous System Agents in Medicinal Chemistry

AU - González-Reyes, Rodrigo E.

AU - Rubiano, María Graciela

PY - 2018/1/26

Y1 - 2018/1/26

N2 - Adequate function of the nervous system depends on the balance of glia-neuron complex interactions. Astrocytes, in particular, are key elements in this process due to the significant participation of these cells in essential properties of the nervous system such as neuroinflammation, regulation of neurotransmitters, release of gliotransmitters and control of synaptic plasticity, among others. Astrocytes express the receptor for advanced glycation end products (RAGE) which is very important in the recognition of endogenous molecules released in the context of infection, physiological stress or chronic inflammation. RAGE can bind several advanced glycation end products, S100 proteins, HMGB1, amyloid-β and other additional DAMP molecules. The nuclear factor-kappa B (NF-κB) transcription pathway is the main intracellular signaling pathway activated by the RAGE receptor, inducing an increase in the expression and release of proinflammatory cytokines. Due to its numerous interactions, RAGE is suspected to be involved in various physiological and pathological processes. It is plausible that a prolonged exposure to RAGE ligands or abnormally increased concentrations of some ligands may induce lengthy periods of intracellular proinflammatory activation, which may induce the appearance of reactive astrocytes involved in the development and/or progression of neurodegenerative disorders. Blocking or reducing the duration of activation of RAGE/NF-κB signaling in astrocytes may become an important therapeutic alternative for the treatment of neurodegenerative disorders in the future.

AB - Adequate function of the nervous system depends on the balance of glia-neuron complex interactions. Astrocytes, in particular, are key elements in this process due to the significant participation of these cells in essential properties of the nervous system such as neuroinflammation, regulation of neurotransmitters, release of gliotransmitters and control of synaptic plasticity, among others. Astrocytes express the receptor for advanced glycation end products (RAGE) which is very important in the recognition of endogenous molecules released in the context of infection, physiological stress or chronic inflammation. RAGE can bind several advanced glycation end products, S100 proteins, HMGB1, amyloid-β and other additional DAMP molecules. The nuclear factor-kappa B (NF-κB) transcription pathway is the main intracellular signaling pathway activated by the RAGE receptor, inducing an increase in the expression and release of proinflammatory cytokines. Due to its numerous interactions, RAGE is suspected to be involved in various physiological and pathological processes. It is plausible that a prolonged exposure to RAGE ligands or abnormally increased concentrations of some ligands may induce lengthy periods of intracellular proinflammatory activation, which may induce the appearance of reactive astrocytes involved in the development and/or progression of neurodegenerative disorders. Blocking or reducing the duration of activation of RAGE/NF-κB signaling in astrocytes may become an important therapeutic alternative for the treatment of neurodegenerative disorders in the future.

UR - http://www.scopus.com/inward/record.url?scp=84991605975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991605975&partnerID=8YFLogxK

U2 - 10.2174/1871524916999160505105121

DO - 10.2174/1871524916999160505105121

M3 - Article

VL - 18

SP - 39

JO - Central Nervous System Agents in Medicinal Chemistry

JF - Central Nervous System Agents in Medicinal Chemistry

SN - 1871-5249

IS - 1

ER -